Mark C. Pyles, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 695 E. 16th St, Suite C, Berwick, PA 18603 Phone: 570-759-1833 Fax: 570-759-0314 |
Roger F Crake, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 695 E 16th St, Suite C, Berwick, PA 18603 Phone: 570-759-3561 Fax: 570-759-0314 |
Ryan J Hawley, DO Surgery Medicare: Accepting Medicare Assignments Practice Location: 751 E 16th St Ste 100, Berwick, PA 18603 Phone: 570-802-5740 Fax: 570-802-5745 |
Dr. Anton Lyubomirov Georgiev, DO Surgery Medicare: Medicare Enrolled Practice Location: 701 E 16th St, Berwick, PA 18603 Phone: 570-759-5453 Fax: 570-759-3473 |
Dr. John Anthony Guerriero Iii, D.O. Surgery - Vascular Surgery Medicare: Accepting Medicare Assignments Practice Location: 1918 W Front St, Berwick, PA 18603 Phone: 570-616-8589 Fax: 570-616-8590 |
News Archive
Favipiravir, an investigational antiviral drug currently being tested in West Africa as a treatment for Ebola virus disease, effectively treated Lassa virus infection in guinea pigs, according to a new study from National Institutes of Health scientists and colleagues.
The Robert Wood Johnson Foundation (RWJF) today announced its selection of Amanda Gaynor Ashley, D.M.D., Ms.Edu., director of the Samuel Simmonds Memorial Hospital Dental Clinic in Barrow, Alaska, to receive a Community Health Leaders Award. She is one of 10 extraordinary Americans who will receive the RWJF honor for 2009 at a ceremony this evening at the Mayflower Hotel in Washington, D.C.
The Center for Business Intelligence (CBI), a division of Advanstar Communications, is pleased to announce the full agenda for the upcoming Biotech/Pharma Finance and Accounting Forum in San Francisco on November 19, 2009.
The study titled, "Does when we eat influence what we eat? A secondary analysis of the UK National Diet and Nutrition Survey" is to be presented as a poster at the European and International Conference on Obesity (ECOICO 2020), held online this year (1-4 September 2020).
Shire plc, the global specialty biopharmaceutical company, announces that the United States District Court for the District of Columbia ("Court"), following extensive briefing by the parties and an oral hearing, has upheld the decision of the U.S. Food and Drug Administration ("FDA") to grant 5-year New Chemical Entity ("NCE") exclusivity to lisdexamfetamine dimesylate-currently marketed by Shire U.S. Inc. for the treatment of attention-deficit hyperactivity disorder under the name VYVANSE(R).
› Verified 1 days ago